Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Document first published:: 21 October 2022
Page updated:: 14 November 2023
Topic:: Specialised commissioning
Publication type:: Policy or strategy

Canakinumab is not recommended to be available as a routine commissioning treatment option for adults and children 2 years and over with Still’s disease refractory to treatment with (or do not tolerate) anakinra and tocilizumab within the criteria set out in this document.

Document

$Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)$

Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

PDF
157 KB
49 pages

Summary

Updated 10 November 2023.

Document

$Clinical panel report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England$

Clinical panel report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England

PDF
142 KB
3 pages

Document

$Clinical priorities advisory group summary report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England$

Clinical priorities advisory group summary report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England

PDF
213 KB
14 pages

Document

$Evidence review: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)$

Evidence review: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

PDF
530 KB
49 pages

Document

$Evidence review: Canakinumab for patients with systemic-onset juvenile idiopathic arthritis (SJIA) refractory to anakinra and tocilizumab (adults and children 2 years and over)$

Evidence review: Canakinumab for patients with systemic-onset juvenile idiopathic arthritis (SJIA) refractory to anakinra and tocilizumab (adults and children 2 years and over)

PDF
550 KB
55 pages

Document

$Engagement report: Canakinumab for patients with adult onset still's disease (AOSD) refractory to or intolerant of anakinra and tocilizumab (adults and children 2 years and over)$

Engagement report: Canakinumab for patients with adult onset still's disease (AOSD) refractory to or intolerant of anakinra and tocilizumab (adults and children 2 years and over)

PDF
285 KB
9 pages

Document

$Equality and Health Inequalities Impact Assessment (EHIA): Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England$

Equality and Health Inequalities Impact Assessment (EHIA): Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England

PDF
129 KB
10 pages

Cookies on the NHS England website

Clinical commissioning policy: canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Summary

Clinical panel report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England

Clinical priorities advisory group summary report: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England

Evidence review: Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over)

Evidence review: Canakinumab for patients with systemic-onset juvenile idiopathic arthritis (SJIA) refractory to anakinra and tocilizumab (adults and children 2 years and over)

Engagement report: Canakinumab for patients with adult onset still's disease (AOSD) refractory to or intolerant of anakinra and tocilizumab (adults and children 2 years and over)

Equality and Health Inequalities Impact Assessment (EHIA): Canakinumab for patients with Still’s disease refractory to anakinra and tocilizumab (adults and children 2 years and over) NHS England